OTC Heartburn Drug Eyed for COVID-19

OTC-Heartburn-Drug-Covid-19

Many people turn to the over-the-counter drug Pepcid (famotidine) after they’ve eaten spicy food, and a new trial is testing whether the heartburn medication may also fight COVID-19.

Pepcid belongs to a group of drugs known as H2 blockers. Other medications in this category include Tagamet (cimetidine) and Zantac (ranitidine). Side effects associated with Pepcid include headache, constipation and diarrhea, though they are not common. Rare side effects include easy bruising/bleeding, mental health/mood changes, and irregular heartbeat.

The idea that Pepcid could potentially treat COVID-19 came from Massachusetts General Hospital infectious disease doctor Michael Callahan, who was already conducting research on avian flu in China in January when COVID-19 began spreading across the country. He travelled to Wuhan and began examining records of thousands of COVID-19 patients, and saw that many suffered from chronic heartburn. He found that those that were already taking Pepcid had a lower mortality rate: 14% compared with 27% for those not on the drug.

Pepcid may be effective against COVID-19 because it binds to an enzyme, preventing the virus from making copies of itself.

Last month, researchers at the Feinstein Institutes for Medical Research, part of Northwell Health, a large hospital system in the New York City area, started enrollment in a trial testing Pepcid, with a goal of 1,174 people total. There will be two arms: one will be given oral hydroxychloroquine and intravenous Pepcid, while the other group will be given hydroxychloroquine and a placebo infusion. Patients in the Pepcid arm will receive the drug at nine times the normal dose.

The FDA recently issued a drug safety communication for hydroxychloroquine and chloroquine following reports of serious heart rhythm problems in some patients with COVID-19 taking one of the medications.

 


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Researchers have managed to create artificial red blood cells that can transport medication. Compared to the popular anticoagulant Warfarin, NOAC’s may be superior for treating atrial fibrillation patients with prior intracranial hemorrhage. Also, surgery may be the preferred choice for reducing leg pain in patients with sciatica.  Synthetic Red Blood…

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

  • Advertisement